IDEAYA Biosciences (IDYA) Stock Price, News & Analysis

Company Overview

IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines for cancer. The company uses insights from tumor genetics and synthetic lethality—the targeting of vulnerabilities created by specific genetic alterations—to identify therapies intended for molecularly defined patient populations.

IDEAYA’s investigational pipeline includes darovasertib (IDE196), a protein kinase C inhibitor being studied in genetically defined cancers, including metastatic uveal melanoma associated with GNAQ or GNA11 mutations. The company is also developing IDE397, an inhibitor of methionine adenosyltransferase 2A (MAT2A) designed to target tumors with MTAP gene deletions. Its research and development activities include discovery programs, clinical trials, and collaborations with pharmaceutical and biotechnology partners.

Founded in 2015, IDEAYA is headquartered in South San Francisco, California, and develops therapies for patients in international clinical and commercial markets through its research programs and industry collaborations. The company is led by Yuval Cohen, Ph.D., who serves as chief executive officer and has been associated with IDEAYA since its founding.

Key Stats

• Today's Range: $35.59 to $37.78
• 50-Day Range: $35.00 to $42.48
• 52-Week Range: $25.35 to $42.68
• Volume: 1.27 million shs
• Average Volume: 1.05 million shs
• Market Capitalization: $3.23 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $52.69
• Consensus Rating: Moderate Buy

IDEAYA Biosciences Stock Analysis - MarketRank™

IDEAYA Biosciences scored higher than 61% of companies evaluated by MarketBeat, and ranked 317th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

IDEAYA Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 13 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

IDEAYA Biosciences has a consensus price target of $52.69, representing about 43.4% upside from its current price of $36.74.

Amount of Analyst Coverage

IDEAYA Biosciences has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for IDEAYA Biosciences are expected to grow in the coming year, from ($4.38) to ($4.00) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IDEAYA Biosciences is -18.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IDEAYA Biosciences is -18.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

IDEAYA Biosciences has a P/B Ratio of 3.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.86% of the float of IDEAYA Biosciences has been sold short.

Short Interest Ratio / Days to Cover

IDEAYA Biosciences has a short interest ratio ("days to cover") of 17.26, which indicates bearish sentiment.

Change versus previous month

Short interest in IDEAYA Biosciences has recently decreased by 1.70%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IDEAYA Biosciences does not currently pay a dividend.

Dividend Growth

IDEAYA Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.91

News Sentiment

IDEAYA Biosciences has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for IDEAYA Biosciences this week, compared to 5 articles on an average week.

MarketBeat Follows

Only 1 people have added IDEAYA Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, IDEAYA Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $382,096.00 in company stock.

Percentage Held by Insiders

4.70% of the stock of IDEAYA Biosciences is held by insiders.

Percentage Held by Institutions

98.29% of the stock of IDEAYA Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 9/24/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IDYA
• CIK: 1676725
• Web: www.ideayabio.com
• Phone: (650) 443-6209
• Fax: N/A
• Employees: 145
• Year Founded: 2015

Price Target and Rating

• Average Price Target for IDEAYA Biosciences: $52.69
• High Price Target: $79.00
• Low Price Target: $30.00
• Potential Upside/Downside: +43.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.94)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$113.70 million
• Net Margins: -75.93%
• Pretax Margin: -74.75%
• Return on Equity: -16.73%
• Return on Assets: -15.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.45
• Quick Ratio: 10.45

Sales & Book Value

• Annual Sales: $234.13 million
• Price / Sales: 13.79
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.67 per share
• Price / Book: 3.15

Miscellaneous

• Outstanding Shares: 87,861,000
• Free Float: 83,732,000
• Market Cap: $3.23 billion
• Optionable: Optionable
• Beta: -0.07